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The exciting development of induced pluripotent stem cells (iPSCs), and the discovery that iPSCs can be
derived from cord blood (CB), combined with the presence of nonhematopoietic stem and progenitor cells
in CB may lead to enhanced therapeutic applicability of this cell source and induce increased CB banking.Hematopoietic stem cells (HSCs) and
progenitors (HPCs) in bone marrow (BM)
have been used clinically for over 40
years. In addition, cord blood (CB) and
public CB banking have worked in
synergy to help patients in need of HSC
and HPC transplants to treat a wide
variety of malignant and nonmalignant
diseases (Broxmeyer and Smith, 2009).
What we know about HSCs and HPCs
and how best to use them for clinical
efficacy developed over decades of
extensive controlled laboratory and clin-
ical studies. This learning process is
ongoing. Despite considerable progress
to date, the field has still not figured out
how to expand human HSCs ex vivo for
effective clinical transplantation, even
though this step was accomplished
decades ago for mouse HSCs and human
and mouse HPCs, highlighting the need
for patience and careful laboratory and
clinical studies before rushing into new
treatment modalities.
The diverse arena of stem cell biology
includes embryonic stem cells (ESCs),
as well as other nonhematopoietic stem
and progenitor cells, such as mesen-
chymal stem or stromal cells (MSCs),
endothelial progenitor cells (EPCs), and
recently induced pluripotent stem cells
(iPSCs) (Yamanaka, 2009). In each case,
many important questions remain to be
answered, including whether many adult
populations are truly stem cells, what their
true range of differentiation capacities
are, to what degree the fate of ESCs,
MSCs, EPCs, other tissue-specific stem
and progenitor cells, and iPSCs can be
finely regulated, and if they will be clini-
cally useful.
Stem cells and the growing field of
regenerative medicine elicit excitement
and anticipation across the globe. How-ever, with hope comes occasional hype
that, in turn, can yield unanticipated false
hope, based on premature clinical efforts
that may provide no recognizable benefit,
which in the end dampens public enthu-
siasm for future applications, or worse,
negatively impacts patients. Although
success can never be guaranteed with
new treatments, we should remain vigilant
and not sacrifice rigorous controls during
experimental design in order to ensure
that any results attained will be informa-
tive, especially at the clinical level. Safety
is a primary concern. In our efforts to
establish the field of CB HSC and HPC
transplantation during the 1980s, we
spent many years on experimentation and
had numerous intense discussions on
the feasibility and ethical considerations
of using CB for transplantation, well
before identifying a first disease to be
treated (Fanconi anemia) and candidate
locale for the first transplant (Dr. Eliane
Gluckman’s group at the Hopital St. Louis
in Paris) (reviewed in Broxmeyer and
Smith, 2009). After deciding on the
disease and transplant unit to target, we
exchanged experimental expertise and
unpublished data with Dr. Gluckman and
her team, prior to releasing the frozen
HLA-matched sibling CB unit from my
proof-of-principle CB bank. As a precau-
tion in case of engraftment failure, we
had the sibling CB donor ready as a
backup in the event that her BM was
needed to rescue the CB recipient. We
hoped not to need her BM, given that
the donor was less than 1 year old
at that time. After the first transplant
successfully demonstrated CB donor
cell engraftment, and an additional three
of four successes were attained (one for
leukemia and two for Fanconi anemia),
I was asked what the future of CB trans-Cell Stem Celplantation might have been, had the first
attempt not succeeded. In response, I
predicted that, at worst, CB engraftment
failure might have resulted in cessation
of subsequent attempts, especially if
the patient was harmed or died, but
more likely a negative outcome would
have substantially slowed efforts toward
future attempts. The important message
to be gleaned from our experience is to
encourage emerging fields that aim to
apply other stem cell populations and
regenerative medicine techniques not to
rush into clinical trial until pros and cons
and ethical concerns are carefully consid-
ered and to ensure that a reasonable
back-up plan is in place before human
intervention is undertaken. This caution,
born of experience, is especially timely
in the context of published reports pur-
porting, without adequate data and
appropriate controls, the usefulness of
CB for regenerative medicine.
With this caveat inmind, recent publica-
tions demonstrating generation of iPSCs
from human CB (Haase et al., 2009; Gior-
getti et al., 2009; Ye et al., 2009), and the
identification of MSCs, EPCs, and other
stem and progenitor cell types in CB
(Broxmeyer and Smith, 2009), indicate
that it is appropriate to consider thepoten-
tial future of CB biology, transplantation,
and banking. Since our initial laboratory
(Broxmeyer et al., 1989) and clinical
(Gluckman et al., 1989) studies that sug-
gested and proved the presence of trans-
plantable HSCs and HPCs in human
umbilical CB, banked allogeneic CB has
been used to treat over 20,000 patients
suffering from the wide range of diseases
treated by BM transplantation. Unrelated
allogeneic CB transplantation is possible
because of the existence of public CB
banks that store HLA-defined CB unitsl 6, January 8, 2010 ª2010 Elsevier Inc. 21
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CB banks that store autologous or related
allogeneic CB and charge both upfront
and maintenance fees. Currently, the
oddsof an individual usingprivately stored
CB are extremely low (Kaimal et al., 2009),
and yet there are three times as many CB
samples stored in private family versus
public banks. Recent cost and use evalu-
ations for these different banks have
been reported by Kaimal et al. (2009).
The emerging fields of stem cell biology
and regenerative medicine have the
potential to influence the growth of both
types ofCBbanks andultimatelymayalter
the existing cost per use calculations.
Examples of developing areas that may
impact the field of CB banking are the
presence of nonhematopoietic stem and
progenitor cells in or produced from CB.
These findings and the potential advan-
tages and limitations of these cells are
discussed below.
iPSCs have been generated from
numerous somatic cell types (reviewed
in Maherali and Hochedlinger, 2008) and
recently also from various subpopulations
of CB, as described below. There is some
suggestion, not yet rigorously proven, that
the more immature the adult starting cell
population, the easier and more efficient
it may be to generate iPSCs. If this
hypothesis is true, CB may represent an
advantageous cell source for iPSC gener-
ation, given that it contains more imma-
ture and cytokine-responsive subsets of
HSC and HPC than adult BM (Broxmeyer
and Smith, 2009). Furthermore, CB HPCs
respond to ex vivo stimulation of prolifer-
ation and expansion more rapidly and,
to a greater extent, and contain longer
teleomeres than BM HPCs. Human
HSC engraftment of nonobese diabetic
(NOD) severe combined immunodeficient
(SCID) mice is greater with CB than BM.
EPCs from CB have greater proliferative
capacity than those from BM (Yoder and
Ingram, 2009). These traits, in part, may
have contributed to the selection of
immature CB subpopulations for use in
iPSC generation. Specifically, Haase
et al. (2009) used lentiviral vector-medi-
ated gene transduction of OCT4, SOX2,
NANOG, and LIN28 into endothelial cells
derived from human CB. The resulting
iPSCs expressed ESC markers OCT4,
SOX2, NANOG, Lin28, SSEA-3, SSEA-4,
and TRA-1-60, with no obvious chromo-
somal abnormalities noted by passage22 Cell Stem Cell 6, January 8, 2010 ª2010 E32. Notably, the efficiency of reprogram-
ming correlated with the proliferative
activity of the targeted endothelial cells.
Functionally, iPSCs differentiated into
endoderm, ectoderm, and mesoderm
germ layers in SCID-beige murine hosts,
and cardiomyocytes with ventricular
and pacemaker-like activity and b-adren-
ergic signaling capacity were produced
in vitro. Taking a different approach, Gior-
getti et al. (2009) used retroviral transduc-
tion of CD133+ CB cells (enriched in HSC
and HPC) with OCT4, SOX2, KLF4, and
c-MYC genes or with only OCT4 and
SOX2. iPSCs maintained a normal karyo-
type for more than ten passages, formed
embryoid bodies with high efficiency,
and gave rise to intratesticular teratomas
containing three embryonic germ layers
in SCID-beige mice. With this method,
iPSCs were generated from frozen CB
stored for more than 5 years. Finally, Ye
et al. (2009) derived iPSCs from CD34+
CB cells that were stored frozen for up
to 8 years and then transduced with retro-
viral vectors expressing OCT4, SOX2,
KLF4, and cMYC. iPSCs expressed TRA-
1-60, as well as endogenous OCT4 and
NANOG, and maintained a normal karyo-
type through at least nine cell passages.
Pluripotency was demonstrated on the
basis of embryoid body formation and
the development of teratomas after injec-
tion into immune-deficient mice.
The CB iPSC studies, though impor-
tant, do not directly address whether CB
will be a more appropriate starting popu-
lation for iPSC production relative to other
cell types, and it remains unclear whether
any iPSCs will be therapeutically useful.
The authors note that the younger age of
CB cells may mean that CB-derived
iPSCs may harbor fewer genetic abnor-
malities and insults, which may allow for
more efficient iPSC generation compared
to other adult somatic cell types, and
thus offer advantages for use in iPSC
production. The availability of banked
CBwas noted as another potential advan-
tage of CB as a starting population.
Successful therapeutic use of nonhema-
topoietic stem and progenitor cells found
in, or generated from, CB will increase
the clinical applicability of CB, thereby
enhancing the need for additional public
banks, as well as for an expanded inven-
tory of HLA-characterized CB units pre-
sent in each bank. Should CB be proven
to offer additional therapeutic uses, thelsevier Inc.likelihood that parents or grandparents
will pay to store their child’s or grand-
child’s CB for personal or related family
use will also increase. The important
caveat, of course, is that such nonhema-
topoietic stem and progenitor cells found
in, or generated from, CB or another other
cell type have not yet demonstrated ther-
apeutic efficacy. Unfortunately, families
are not necessarily informed that use of
these non-HSC and HPCs remains an
unproven therapeutic concept. It is impor-
tant that CB banks, whether private family
or public, do not overstate or oversell the
efficacy of their product without proof that
the benefits are real, rather than merely
potential advantages. With numerous
births a year, the vast majority of which
have not been collected for CB banking,
I don’t consider it likely that public banks
will experience a decline in donations
because of private family banking. In
fact, I predict that with proper and honest
advertising and with more infrastructure
and government support, the number of
parents willing to donate to public banks
will increase. In the end, the choice of
donating to a public or private family
bank is a private parental decision, but
one that needs to be made with appro-
priate information, not misinformation.
On the experimental side, iPSC tech-
nology has advanced rapidly as a result
of the efforts of many labs worldwide.
For example, viable mice have been
generated from mouse iPSCs through
tetraploid complementation, a mouse
model of sickle cell anemia was treated
with autologous iPSCs after gene correc-
tion of the human sickle hemoglobin, and
iPSCs have been generated from different
patients, thereby allowing disease model-
ing (Saha and Jaenisch, 2009). Further-
more, additives are being evaluated for
the capacity to enhance genetic factor-
mediated reprogramming or to replace
genetic intervention completely (reviewed
in Feng et al., 2009). Successful iPSC
generation remains variable and ineffi-
cient, and several methods to overcome
this hurdle, such as disabling the p53
tumor-suppressor gene, also promote
the possibility that resulting lines will
themselves give rise to cancer. Further-
more, little is known regarding the effi-
ciency and specificity of the processes
used to generate differentiated progeny
from iPSCs derived from various somatic
sources and how complex it may be to
Cell Stem Cell
Forumfinely regulate these protocols. Fully re-
programmed iPSCs attain an essentially
ESC-like state, but ESCs themselves
can manifest a degree of genetic insta-
bility, especially under stress (Mantel
et al., 2007). Thus, the field is dealing
with safety problems at the level of the
iPSC itself, as well as the purity and func-
tion of differentiated cells produced from
the iPSCs. With these successes and
challenges in mind, we can consider
how CBmight compare to other cell sour-
ces for iPSC generation.
A concern when planning to transplant
iPSC-derived cells is their immune status.
The level of GVHD observed in any trans-
plant recipient is enhanced in proportion
to HLA disparity, and even perfectly
HLA-matched allogeneic cells elicit
some level of GVHD, even with prophy-
laxis. CB may, due in part to its relatively
naive immune state, offer an advantage
over adult somatic cells for use in gener-
ating human iPSCs for allogeneic trans-
plantation. However, extensive in vitro
manipulation during the derivation and
subsequent differentiation of CB iPSCs
may increase their immunogenicity as
a result of upregulation of major and/or
minor histocompatibility or other loci. In
fact, past attempts to expand CB HSCs
and HPCs ex vivo for clinical use have eli-
cited enhanced levels of chronic GVHD,
and it may be that even newer ex vivo
methods used to expand cells will have
a similar negative outcome. This possi-
bility will need to be carefully assessed,
especially with regard to the generation
of nonhematopoietic cells.
Although it is clear that iPSCs can be
generated from cryopreserved CB (Gior-
getti et al., 2009; Ye et al., 2009), we
don’t know how well units of cryopre-
served and fresh CB compare in terms
of their iPSC derivation efficiency, the
genetic stability of resulting lines and their
differentiated progeny, or how the length
of time spent in frozen storage influences
these parameters. Our work with cryopre-
served CB demonstrated high-efficiency
recovery of functional HSCs and HPCs
after 15 years as assessed in vivo and
in vitro (Broxmeyer, et al., 2003), and
our unpublished data demonstrates
similar recovery of HSCs and HPCs
after 23+ years of cryopreservation. The
longest a CB unit has been stored and
used successfully for HSC and HPC
engraftment in humans is in the 10–12year range, whereas CB samples are
retained for much longer periods, and
thus may represent a valuable source of
starting material for iPSC generation. It is
imperative that the functional capacity of
human CB for this application be studied
in much greater detail, and after much
longer periods of storage than the 5 to
8 + years currently reported. Furthermore,
although iPSCs have been generated
from subsets of frozen CB, the cryopres-
ervation technique used for HSC and
HPCs may not be optimal for generation
of iPSCs. If iPSCs generated from CB
prove to be of clinical utility, the question
of whether iPSCs should be derived prior
to freezing or after thawing of the sample
will need to be addressed. One might
propose to isolate specific subpopula-
tions intended for eventual reprogram-
ming prior to cryopreservation, rather
than freezing unseparated cord cells.
However, this approach would be unwise,
given that it remains to be seen which
cells are best suited for reprogramming,
and prefractioning would result in the
loss of not only the HSC and HPCs but
also of other potentially clinically relevant
cells. Obviously, already banked units of
CB will need to have iPSC generated
after defrost, and it may be best to limit
iPSC generation to postthaw samples.
Of note, the impact of cryopreservation
on the function of any established iPSC
line is not yet known, regardless of the
somatic cell of origin.
Although it is not inconceivable that CB
iPSCs may offer an alternative source of
HSCs and HPCs for transplantation, it is
not clear at this stage whether a sufficient
number of hematopoietic cells of the
quality of those already found in CB could
be generated to warrant this type of effort.
In fact, it is likely that CB iPSCs will be
more valuable as a source of other types
of cell or tissue stem and progenitors
and their progeny. In particular, the poten-
tial to make multiple cell lineages from
a single, genetically identical cell source
is one of the most desirable qualities of
iPSCs derived from any starting popula-
tion. That said, it remains unclear whether
iPSCs derived from CB will be better able
to generate nonhematopoietic cell types
than iPSCs derived from other tissues.
Even if their capacities are only roughly
equivalent, the existence of stored, HLA-
typed CB units could provide an argu-
ment in favor of using CB for this purpose.Cell Stem CelIn addition to HSCs and HPCs, other
known stem and progenitor cell types
are present in CB that may harbor as yet
untested, and thus presently unproven,
therapeutic value. This list includes but is
not necessarily limited to MSCs and
EPCs. MSCs exhibit extensive prolifera-
tive capacity in vitro and can differentiate
into bone, fat, and cartilage. MSCs may
possess immunomodulating activity, but
there is a paucity of information regarding
characterization and function of MSCs
(Prockop, 2009). MSCs from CB may be
of future use in regenerative medicine,
but given that only a subset of CB units
contain MSCs, possibly because of
decreased frequency of these cells in
CB versus BM (Broxmeyer and Smith,
2009), CB may not represent an appro-
priate source of MSCs unless the popula-
tion isolated from CB samples are found
to be more potent than those extracted
from BM. EPCs with extensive prolifera-
tive capacity are also found in CB, albeit
with relatively low frequency. Accurate
definition of EPCs is controversial, as is
their potential role in angiogenesis (Yoder
and Ingram, 2009). Better understanding
of the phenotypic and functional charac-
teristics, frequency and proliferative
potential, and immunogenicity of MSCs
and EPCs present in CB versus other
tissue sources, such as BM, is needed
before the clinical use of these popula-
tions in general, as well as for CB-derived
cells specifically, should be considered
for regenerative medicine.
Recent excitement with regard to stem
and progenitor cell biology as a field, and
iPSCs in particular, is warranted in terms
of basic biological insights into mecha-
nisms of cell production, differentiation,
and action. However, many unknowns
remain regarding the realistic potential of
iPS and other cell types for regenerative
medicine. The clinical potential and safety
of these cells and their differentiated
offspring have yet to be determined, let
alone whether CB may turn out to be
a preferable source of nonhematopoietic
stem cells and of starting material for
iPSC generation. We can be cautiously
optimistic and open-minded that clinical
utility will eventually result from these
evolving fields of study, but we must be
realistic and not allow the predicted
potential of these cells to get ahead of,
or supersede, the rigorous science and
controlled clinical efforts necessary tol 6, January 8, 2010 ª2010 Elsevier Inc. 23
Cell Stem Cell
Forumdetermine whether true applicability for
these cells exists, and whether the cells
are safe and efficacious.
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